Semisynthetic Analogs of the Antibiotic Fidaxomicin—Design, Synthesis, and Biological Evaluation
Open Access
- 14 October 2020
- journal article
- letter
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (12) , 2414-2420
Abstract
The glycoslated macrocyclic antibiotic fidaxomicin (1, tiacumicin B, lipiarmycin A3) displays good to excellent activity against Gram-positive bacteria and was approved for the treatment of Clostridium difficile infections (CDI). Among the main limitations for this compound, its low water solubility impacts further clinical uses. We report on the synthesis of new fidaxomicin derivatives based on structural design and utilizing an operationally simple one-step protecting group-free preparative approach from the natural product. An increase in solubility of up to 25-fold with largely retained activity was observed. Furthermore, hybrid antibiotics were prepared that show improved antibiotic activities.Keywords
All Related Versions
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (200021_182043, 31003A_153349/1)
- Deutsche Forschungsgemeinschaft (GRK 2158, P4)
- Lungenliga Schweiz (2018-02)
This publication has 50 references indexed in Scilit:
- From natural product to marketed drug: the tiacumicin odysseyNatural Product Reports, 2012
- Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA SynthesisClinical Infectious Diseases, 2012
- New target for inhibition of bacterial RNA polymerase: ‘switch region’Current Opinion in Microbiology, 2011
- Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficileJournal of Medical Microbiology, 2011
- Characterization of Tiacumicin B Biosynthetic Gene Cluster Affording Diversified Tiacumicin Analogues and Revealing a Tailoring DihalogenaseJournal of the American Chemical Society, 2010
- Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistanceExpert Opinion on Drug Discovery, 2010
- The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic siteThe EMBO Journal, 2010
- In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus spp. and Enterococcus sppAntimicrobial Agents and Chemotherapy, 2010
- Frequency and characterisation of spontaneous lipiarmycin-resistant Enterococcus faecalis mutants selected in vitroInternational Journal of Antimicrobial Agents, 2009
- Initiation of transcription in vitro is inhibited by lipiarmycinJournal of Molecular Biology, 1979